• News
  • Movies
  • Money
  • Health
  • Videos
More
Hero Hero
  • Kerala
  • India
  • NRI
  • World
  • Offbeat
  • Talkathon
  • Good News
  • Crime Beat

2,24,301 beneficiaries given COVID-19 vaccine so far; 447 cases of adverse effect reported: Govt

"Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated," Additional Secretary Manohar Agnani said.

Jan 17, 2021, 10:01 PM IST
T- T T+
covid vaccine
X
×
Representational image | Photo: PTI

New Delhi: A total of 2,24,301 beneficiaries have been inoculated with COVID-19 vaccine so far, out of which only 447 adverse events following immunisation (AEFI) were reported, the Union Health Ministry said on day two of the nationwide vaccination drive on Sunday.

Addressing a press briefing, the ministry's Additional Secretary Manohar Agnani said out of the 447 adverse events following immunisation, only three required hospitalisation.

"Today being Sunday, only six states conducted vaccination drive and in 553 sessions a total of 17,072 beneficiaries were vaccinated," he said.

The six states where the vaccination drive was carried out on Sunday are Andhra Pradesh, Arunachal Pradesh, Karnataka, Kerala, Manipur and Tamil Nadu, he added.

Agnani said a total of 2,24,301 beneficiaries have been vaccinated till January 17 as per provisional reports, adding that 2,07,229 of them received the jabs on day one of the drive.

"A total of 447 AEFI have been reported on January 16 and 17, out of which only three required hospitalisation. Most of the AEFI reported so far are minor like fever, headache, nausea," he said.

He said a meeting was held with all states and union territories on Sunday to review the progress of the drive, identify bottlenecks and plan corrective actions.

Prime Minister Narendra Modi rolled out the world's largest inoculation drive against COVID-19 on Saturday and said the two vaccines being deployed will ensure a "decisive victory" for India against the pandemic.

India has approved two vaccines -- Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India -- for emergency use in the country.

According to the government, the shots will be offered first to an estimated one crore healthcare workers and around two crore frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities.

PTI

 

PRINT
EMAIL
COMMENT
 

Related Articles

Kerala reports 3,254 new COVID cases on Sunday; test positivity rate at 5.18 percent
News |
News |
Vaccination for people aged above 60 yrs to start from Monday
News |
India records 16,752 fresh COVID-19 cases, biggest single-day jump in 30 days
News |
Kerala reports 3,792 new Covid-19 cases, 4,650 recoveries; test positivity rate at 5.14 percent
 
 
  • Tags :
    • COVID-19 Vaccine
    • Covid-19 Vaccine
    • COVID-19
    • Coronavirus
    • Coronavirus Vaccine
More from this section
Amit Shah
Congress collapsing across India due to dynasty politics, says Amit Shah
modi
PM calls for 100-day campaign to clean up water bodies, harvest rain water
covid
India records 16,752 fresh COVID-19 cases, biggest single-day jump in 30 days
Covid Vaccine
Private hospitals can charge up to Rs 250 per dose for COVID-19 vaccine
flight
DGCA allows airlines to provide concession in air fares to customers with no baggage
News in Videos
News+ Kerala India NRI World Columns Features Offbeat Good News Crime
Leisure Movies & Music Sports Travel Books
Learn Money Education Agriculture
Lifestyle Health Tech Food Astrology
Multimedia Gallery Videos Mojo News News In Pics
Our Network Malayalam Print Mathrubhumi News TV Kappa TV Club FM Seed Silver Bullet FindHome Media School MBIFL Redmic
E-Paper
Subscription
Buy Books
Magazines
Classifieds
Archives
 
  • E-Paper
  • Subscription
  • Buy Books
  • Magazines
  • Classifieds
  • Archives
© Copyright Mathrubhumi 2021. All rights reserved.
About Us Contact Us Privacy Policy
Terms of Use Archives
Ad Tariff Download App Classifieds
Buy Books Subscription e-Subscription
 
         
© Copyright Mathrubhumi 2021. All rights reserved.